Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?

Core Viewpoint - Shares of Amylyx Pharmaceuticals, Inc. (AMLX) have increased by 3.6% over the past four weeks, closing at $14.31, with a potential upside indicated by Wall Street analysts' mean price target of $18.5, suggesting a 29.3% increase [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $3.85, where the lowest estimate is $12.00 (indicating a 16.1% decline) and the highest is $25.00 (indicating a 74.7% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about AMLX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 8.8% over the past month, with two estimates increasing and no negative revisions [12] Zacks Rank and Investment Potential - AMLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for potential investment [14]